idazoxan has been researched along with Parkinson Disease in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, C; Liu, J; Wang, HS; Wang, T; Wang, Y | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Goldenberg, AA; Klioueva, A; Lindenbach, D; Surrena, MA; Tignor, S; Walters, H | 1 |
| Gerlach, M; Halley, P; Riederer, P; van den Buuse, M | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Lee, J | 1 |
| Boulton, RM; Hudson, AL; Nutt, DJ; Pearson, SJ; Reynolds, GP | 1 |
| Gargalidis-Moudanos, C; Javoy-Agid, F; Parini, A; Pizzinat, N; Remaury, A | 1 |
| Ballesteros, J; Jaúregui, JV; Meana, JJ; Ruiz, J; Soto, J; Ulibarri, I | 1 |
| Bezard, E; Brefel, C; Gross, CE; Ladure, P; Peyro-Saint-Paul, H; Rascol, O; Tison, F | 1 |
| Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P | 1 |
| Iakovidou, E; Lees, AJ; Manson, AJ | 1 |
| Agid, Y; Arnulf, I; Bejjani, B; Bonnet, AM; Brefel-Courbon, C; Descombes, S; Fabre, N; Montastruc, JL; Peyro-Saint Paul, H; Rascol, O; Thalamas, C; Vidailhet, M | 1 |
2 trial(s) available for idazoxan and Parkinson Disease
| Article | Year |
|---|---|
Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Failure | 2000 |
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects | 2001 |
9 other study(ies) available for idazoxan and Parkinson Disease
| Article | Year |
|---|---|
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; Dyskinesia, Drug-Induced; Hippocampus; Idazoxan; Levodopa; Male; Molecular Targeted Therapy; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Propranolol; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sympathectomy, Chemical | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Benserazide; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Facial Asymmetry; Idazoxan; Levodopa; Locomotion; Oxidopamine; Parkinson Disease; Piribedil; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Statistics, Nonparametric; Upper Extremity | 2013 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Haloperidol; Idazoxan; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpine | 2005 |
Imidazoline binding sites in Huntington's and Parkinson's disease putamen.
Topics: Adrenergic alpha-Antagonists; Brain Chemistry; Humans; Huntington Disease; Idazoxan; Imidazoline Receptors; Parkinson Disease; Putamen; Receptors, Drug | 1996 |
I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Brain; Cerebral Cortex; Female; Humans; Idazoxan; Imidazoline Receptors; Male; Mitochondria; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Postmortem Changes; Putamen; Receptors, Drug; Tritium; Tyramine | 1997 |
I2-imidazoline receptors in platelets of patients with Parkinson's disease and Alzheimer's type dementia.
Topics: Alzheimer Disease; Antiparkinson Agents; Blood Platelets; Cell Membrane; Humans; Idazoxan; Imidazoles; Imidazoline Receptors; Kinetics; Parkinson Disease; Receptors, Drug; Reference Values; Selegiline | 1999 |
Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Female; Idazoxan; Macaca fascicularis; Motor Skills Disorders; Parkinson Disease | 1999 |
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Idazoxan; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Norepinephrine; Parkinson Disease | 2000 |